BioXcel Therapeutics, Inc. (BTAI)
|52 Week Range||8.795-34.125|
|1y Target Est||-|
|DCF Unlevered||BTAI DCF ->|
|DCF Levered||BTAI LDCF ->|
|Debt / Equity||168.13%||Buy|
Upgrades & Downgrades
Latest BTAI news
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
1 June 2023
NEW HAVEN, Conn., June 01, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medici...
BioXcel Therapeutics: Serenity III Part 1 Didn't Meet Primary Endpoints, Part 2 Will
28 May 2023
BioXcel has just published the results of the first part of the Serenity III trial in which, although clinically good results, it has not been able to achieve statistically significant. This first par...
Why Shares of BioXcel Therapeutics Are Dropping Thursday
25 May 2023
BioXcel Therapeutics got approval last year for Igalmi to treat acute agitation in adults with schizophrenia or bipolar disorder. The drug is in a trial to treat patients in an at-home setting.
BioXcel Stock Crashes 22% As Bid To Double Its Market Appears Less Certain
25 May 2023
Shares of BTAI stock plummeted after BioXcel's Igalmi missed the mark in patients with agitation due to schizophrenia or bipolar disorders. The post BioXcel Stock Crashes 22% As Bid To Double Its Mark...
Why These 3 Nasdaq Stocks Were Glowing Green This Week
11 May 2023
A fair number of Nasdaq-listed growth stocks moved higher this week. CRISPR Therapeutics, BioXcel Therapeutics, and Verve Therapeutics were among the biggest winners this week.
Why BioXcel Therapeutics Stock Marched Higher Today
8 May 2023
BioXcel Therapeutics announced 2023 first-quarter earnings today. While revenue for the three-month period wasn't a needle-mover, investors appear to be intrigued by a series of upcoming trial readout...
BioXcel Therapeutics, Inc. (BTAI) Q1 2023 Earnings Call Transcript
8 May 2023
BioXcel Therapeutics, Inc. (NASDAQ:BTAI ) Q1 2023 Earnings Conference Call May 8, 2023 8:00 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Rob Risinger - Chief Medical Offi...
BioXcel Therapeutics to Present at the BofA Securities 2023 Health Care Conference
2 May 2023
NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicin...
BioXcel Therapeutics: All Eyes On Igalmi's Ramp, Reiterating Hold Rating
26 April 2023
BioXcel Therapeutics: All Eyes On Igalmi's Ramp, Reiterating Hold Rating.
BioXcel Therapeutics to Report First Quarter 2023 Financial Results on May 8, 2023
24 April 2023
NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medic...
BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Stock Value >
Financial Summary > Financial Statements > Financial Quarter Statements > Ratios Analysis > Dupont Analysis > Free Cash Flow > Operating Data > Balance Sheet Data >